US 12,441,679 B2
Acrylamide-substituted indane compounds and therapeutic use thereof
Eykmar Fett, Paris (FR); and Olivier Venier, Paris (FR)
Assigned to Sanofi, Paris (FR)
Appl. No. 18/018,459
Filed by Sanofi, Paris (FR)
PCT Filed Jul. 29, 2021, PCT No. PCT/EP2021/071237
§ 371(c)(1), (2) Date Jan. 27, 2023,
PCT Pub. No. WO2022/023460, PCT Pub. Date Feb. 3, 2022.
Claims priority of application No. 20305876 (EP), filed on Jul. 30, 2020.
Prior Publication US 2023/0265047 A1, Aug. 24, 2023
Int. Cl. C07C 233/09 (2006.01)
CPC C07C 233/09 (2013.01) [C07C 2602/08 (2017.05)] 20 Claims
 
1. A compound of formula (I)

OG Complex Work Unit Chemistry
wherein
R1 is chosen from:
an oxygen atom, and
a group —N(H)— or a group —N(R8)-,
wherein R8 is a (C1-C4) alkyl group;
R2 is chosen from:
a phenyl group unsubstituted or substituted with one or more R4 groups;
a benzyl group unsubstituted or substituted with one or more R5 groups;
a (C4-C8) cycloalkyl group unsubstituted or substituted with one or more R5 groups;
a heteroaryl group unsubstituted or substituted with one or more R5 groups; and
a (C1-C6) alkyl group substituted with one or more fluorine atoms;
R4 is chosen from:
a halogen atom;
a (C1-C4) alkyl group unsubstituted or substituted with one or more fluorine atoms;
a (C1-C4) alkoxy group unsubstituted or substituted with one or more fluorine atoms;
a C(O)—O—(C1-C4) alkyl group;
a (C3-C6) cycloalkyl group;
a (C1-C4) alkylthio group; and
a pentafluorosulfanyl group;
R5 is chosen from:
a halogen atom; and
a (C1-C4) alkyl group unsubstituted or substituted with one or more fluorine atoms;
R3 is chosen from:
a hydrogen atom, and
a (C1-C4) alkyl group;
R6 is chosen from a hydrogen atom or a halogen atom;
R7 is independently chosen from:
a halogen atom;
a (C1-C4) alkyl group;
a hydroxy group; and
a (C1-C4) alkoxy group; and
n is 0, 1 or 2;
or a pharmaceutically acceptable salt thereof.